Erytech Pharma ()
Founded in Lyon (France) in 2004, Erytech Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, Erytech has developed a pipeline of product candidates targeting markets with high unmet medical needs. Erytech’s initial focus is on the treatment of cancers, by depriving tumors of nutrients necessary for their survival.
Role and Commitment of key persons (including supervisors)
Françoise Horand, R&D Operations Director, overall supervision (20%) Dr. Agnès Cibiel, Project Manager, supervision (80%)
Key Research Facilities, Infrastructure and Equipment
Erytech Pharma has state-of-the-art equipments essential for developing novel RBC based therapeutic products. Infrastructures include fully equipped cell culture and molecular biology labs with automated hematology analyzers, flow cytometer, incucyte, and access to LORRCA system necessary to characterize engineered RBC properties. In addition, a team of 35 highly qualified research technicians, engineers and scientists will be involved in the research supervision and training of the recruited Early-Stage Researchers.
Status of Research Premises
Erytech Pharma is renting its own independent space in Bioparc Lyon. Erytech possesses its ERYCAPS platform to encapsulate therapeutic molecules into RBC. Erytech possesses also its own equipment to characterize RBC before and after encapsulation process.
Previous Involvement in Research and Training Programmes
- Graspanc project- Bpifrance funding (RDI)- 2006 Objective: phase I clinical development of eryaspase in pancreatic cancer (Not a collaborative project)
- GRARA project- Research National Agency (ANR)-2008 Objective: hemoglobin allosteric effector entrapment into erythrocytes for preventing and treating vaso-occlusive crisis in patients with sickle cell anemia . (Partnership project with Erytech as leader)
- Polybio project -Interministerial funding (FUI)-2009 Objective: Interaction between biologic fluid and polymers (Partnership project with Erytech as partner only)
- Previous supervision: A. Scheer supervised more than 100 scientists with PhDs in industry; A. Cibiel supervised 1 MSc and 2 undergrads.
Relevant Publications and/ or Research/ Innovation Product
- TEDAC project funded by Bpifrance since 2011 Objective: Personalized treatment of cancers resistant to radio/chemotherapy TEDAC Project
- Present supervision: A. Scheer supervises 8 scientists with PhDs in industry; A.Cibiel supervises 2 PhDs and 1 PhD student. • Gay F et al. Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6. Cancer Med. 2017 Jun;6(6):1437-1452 • Bourgeaux V et al. Drug-loaded erythrocytes: on the road toward marketing approval. Drug Design Development and Therapy. 2016; 10, 665–676. • Godfrin Y and Bax BE. Enzyme bioreactors as drugs. Drugs of the Future. 2012; 37(4): 263-272. • Dufour et al. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas. 2012 Aug;41(6):940-8. • Lamarre Y et al. Effect of inositol hexaphosphate-loaded red blood cells (RBCs) on the rheology of sickle RBCs. Transfusion. 2013; 53:627-636.